Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial — Masatoshi Kudo (2020) | RDL Network
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
Ramucirumab after prior sorafenib improved PFS and OS compared with placebo, with a manageable safety profile, in the Japanese REACH-2 subpopulation, consistent with the overall REACH-2 study results. Ramucirumab is the first agent to demonstrate clinical benefit for Japanese patients with HCC in the second-line setting.
Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Éric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min‐Hua Jen, N. Drove Ubreva, Ryan C. Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X. Zhu
Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun‐Ming Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu
Masatoshi Kudo, Finn R.S., Manabu Morimoto, Rau K.-M., Masafumi Ikeda, Yen C.-J., Galle P.R., Llovet J.M., Bruno Daniele, Lim H.Y., M. W., Reigetsu Yoshikawa, Kenichi Nakamura, K. Liang, C. Wang, Paolo Abada, Widau R.C., Xiaoli Zhu
Andrew X. Zhu, Ryan David Nipp, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Jean-Frédéric Blanc, Takuji Okusaka, Ian Chau, David Cella, Allicia C. Girvan, Jonathon Gable, Lee Bowman, Chunxiao Wang, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.